FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Hewes L. Becker 2. Issuer Name and Ticker or Trading Symbol Blueprint Medicines Corp [ BPMC ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Medical Officer
(Last)         (First)         (Middle)
C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET
3. Date of Earliest Transaction (MM/DD/YYYY)
11/15/2021
(Street)
CAMBRIDGE, MA 02139
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  11/15/2021    M(1)    729  A $66.24  26916  D   
Common Stock  11/15/2021    S(1)    729  D $115.49  26187  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)  $66.24  11/15/2021    M (1)       729    (2) 6/1/2030  Common Stock  729  $0  24792  D   

Explanation of Responses:
(1)  Effected pursuant to a trading plan adopted on August 13, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
(2)  This option was granted on June 1, 2020. This option vested with respect to 25% of the shares underlying the option on June 1, 2021 and as to an additional 1/48th of the shares underlying the option each month thereafter.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Hewes L. Becker
C/O BLUEPRINT MEDICINES CORPORATION
45 SIDNEY STREET
CAMBRIDGE, MA 02139


Chief Medical Officer

Signatures
/s/ Ariel Hurley, Attorney-in-Fact 11/17/2021
**Signature of Reporting Person Date
Blueprint Medicines (NASDAQ:BPMC)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Blueprint Medicines Charts.
Blueprint Medicines (NASDAQ:BPMC)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Blueprint Medicines Charts.